ATHENasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as PRNAF
ALTERITY THERAPEUTICS LTD
Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Aug 28, 2026
$2.43−0.19 (-7.25%)
Close on Oct 19, 2026
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Return on assets | – | 70.4% | – | |
| Current ratio | 15.88 | 10.92 | 14.52 | |
| Capex to revenue | 21.1% | – | – | |
| Diluted shares | 11M | 34M | 210M |
Where the cash went
Fiscal 2022 to 2026, five years combined
Alterity Therapeutics generated A$78.95M from operations and spent A$102.18K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
A$78.95M
Used
A$102.18K
Capital expenditureA$102.18K100%DividendsA$00%Share buybacksA$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
1of 3 tests passed in fiscal 2026. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero-A$22.52M
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net income-A$22.52M vs –
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose12.98 → 14.52
- No dilutionShare count did not rise128M → 210M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –